Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Wharton flagged that the combination would create India's largest pharma and the world's fifth-largest specialty generics maker, but that 'most analysts were…
Daiichi Sankyo exited its 9% Sun Pharma stake worth ~$2B — less than half the $4.2B it paid for Ranbaxy in 2008 — confirming the deal as a face-saving exit…
Sun Pharma paid $485M to settle a long-running US antitrust suit inherited via Ranbaxy — a concrete example of the regulatory and legal liabilities embedded in…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sun Pharma agreed to acquire 100% of Daiichi Sankyo subsidiary Ranbaxy Laboratories in an all-stock transaction valued at approximately $4B (US$3.2B equity plus $800M assumed debt). The combination created India's largest pharmaceutical company and the world's fifth-largest generics maker; closed in calendar 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited (this deal) | 2014 | $4.0B | 66 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2015 | $4.0B | 52 |
| Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc. | 2012 | $230M | 49 |
| Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) | 2012 | $60M | 34 |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
| Sun Pharmaceutical Industries Ltd. / Checkpoint Therapeutics, Inc. | 2025 | $355M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
← Browse all deals · How we score deals
More: 2014 deals · Sun Pharmaceutical Industries Ltd. deals · Other deals